Abstract α 1 -Adrenergic-signaling in cardiac myocytes activates the skeletal muscle α-actin gene through an MCAT cis-element, the binding site of the TEF-1 family of transcription factors.
Introduction
Cardiac myocytes respond to α 1 -adrenergic stimulation by a progressive hypertrophy (1) accompanied by a characteristic reactivation of many fetal genes, including skeletal muscle α-actin (2), β myosin heavy chain (3) and b-type natriuretic peptide (4) . The hypertrophic response of these promoters requires slightly different MCAT elements. MCAT elements are found in the promoters of many genes expressed in cardiac and skeletal muscle cells (5) and are bound by members of the Transcriptional Enhancer Factor-1 (TEF-1) family, originally isolated as a transcription factor required for SV40 enhancer function in HeLa cells (6, 7) . Thus, a role for TEF-1 in mediating the α 1 -adrenergic response of MCAT-dependent promoters to hypertrophic signals has been proposed (4, (8) (9) (10) .
Ablation of TEF-1 expression in the mouse leads to abnormal cardiac development and embryonic lethality (11), but does not prevent the expression of MCAT-dependent cardiac genes, suggesting that other MCAT-binding factors exist. We cloned a cDNA encoding a TEF-1 related protein, RTEF-1, from an adult human heart cDNA library (12) demonstrating the existence of at least two functional MCAT-binding factors in human cardiac myocytes. The effect of TEF-1 and RTEF-1 over-expression on the α 1 -adrenergic activation of the skeletal muscle α-actin promoter was tested in cultured neonatal rat cardiac myocytes. Whereas TEF-1 had no effect, RTEF-1 potentiated the α 1 -adrenergic induction of the skeletal muscle α-actin promoter, suggesting that RTEF-1 can mediate α 1 -adrenergic signaling in adult cardiac myocytes (13) . Site-directed mutagenesis identified potential targets of α 1 -adrenergic signaling in RTEF-1 (14) . However, it remains uncertain whether RTEF-1 is the only target of the MCAT-dependent α 1 -adrenergic response in neonatal rat cardiac myocytes. A third TEF-1 family member named ETF, for embryonic TEA domain containing factor (15) , is expressed in the cerebellum and testis in the mouse embryo. A fourth TEF-1 factor called DTEF-1 is highly expressed in the chicken heart (16). Although not cardiac-enriched in the mouse, DTEF-1 (also called ETFR-1 or is also expressed in the adult mouse (17) and human heart (18) . Moreover, whereas DTEF-1 is detected in the mid-to late-gestational fetal mouse heart (19, 20) , RTEF-1 is not detected at this Cell culture and transfection-Neonatal rat cardiac myocytes were isolated, cultured and were transfected using the calcium phosphate precipitation method as described previously (14) . A total of 20 µg DNA was added per plate; 5µg of reporter plasmid (-113 SKA), 100 ng of CMV driven expression plasmid (pXJ40, pXJ40-TEF-1A, pXJ40-DTEF-1, and pXJ40-TDT) and adjusted to 20 µg with pBluescript plasmid. Our previous studies showed that 100 ng of expression vector produced the optimal response (13, 14) . The day after transfection, medium was replaced with serum-free medium containing either 100 µM vitamin C vehicle or 100 µM of the α 1 -adrenergic agonist phenylephrine. Cells were maintained two additional days in serumfree medium and then harvested for the CAT assay.
CAT assay-Chloramphenicol acetyl transferase (CAT) activity was assessed as described previously (14) . Fold activities (+/-standard deviation) are expressed relative to the empty expression vector set at 1 fold, and represent the percent conversion from unacetylated to 7 acetylated chloramphenicol, for each promoter reporter plasmid. By independent samples T test, mean fold activities were considered different from 1 fold at the 95% confidence interval.
Nuclear protein extracts-Nuclear protein extract from cultured neonatal rat cardiac myocyte were prepared essentially as described by Farrance and Ordahl (23) . For nuclear extracts from transfected cells, 5 x 10 6 cardiac myocytes were plated on 100mm culture dishes and transfected as described above, except that 13 µg of the expression plasmids were used. Cells were harvested 24 hours after transfection. Nuclear protein concentration was determined by the bicinchoninic acid method (Sigma) against a bovine serum albumin standard curve.
Gel mobility shift assay-The gel mobility shift assays were carried out as described previously, using the MCAT element of the mouse skeletal α-actin promoter (14) . (Fig. 1) . Not counting sites that are shared between TEF-1 and DTEF-1 (and therefore are unlikely to contribute to functional differences), 6 sites in TEF-1 and 9 sites in DTEF-1 were Thus, mechanisms other than nuclear localization such as changes in cofactor interaction might operate if GSK3 inactivation plays a role in modulating DTEF-1 function.
As for the MAPK and PKC sites, all but one appear to cluster in a narrow region just carboxy-terminal to the DNA binding domain of DTEF-1. The functional significance of this domain was tested in cardiac myocytes by constructing a chimeric expression vector between TEF-1 and DTEF-1 (Fig. 1B) .
The effect of DTEF-1 over-expression was tested on a skeletal muscle α-actin promoterdriven CAT reporter construct in cardiac myocytes under basal conditions and after α 1 -adrenergic stimulation (Fig. 2 , n ≥ 6). As reported previously (13) , the skeletal muscle α-actin TDT protein is not supershifted by the TEF-1-specific antibody because the epitope recognized by the antibody lies within the highly divergent swapped domain (see Fig. 1A ).
DTEF-1 is present and phosphorylated in rat neonatal cardiac myocytes.
We have shown previously that 10-15% of the MCAT-binding activity in cardiac myocytes is contributed by transcription factors other than TEF-1, presumably by other members of the TEF-1 family (14, 22) . To confirm that DTEF-1 contributes to the non-TEF-1 MCAT-binding activity in cardiac myocyte nuclear extracts, a peptide-specific antibody to DTEF-1 was obtained (Fig. 3A) .
Specificity of the antibody was tested by immunoblotting using nuclear extracts from H1299 cells over-expressing TEF-1, RTEF-1 and DTEF-1 ( Fig. 3B ) and by gel mobility shift assays using in vitro translated TEF-1, RTEF-1 and DTEF-1 proteins (Fig. 3C ). The antibody was specific for DTEF-1 since it recognized DTEF-1, and not other TEF-1 family members, in both western and gel mobility shift analyses.
The DTEF-1 antibody was used to determine if DTEF-1 is expressed in neonatal rat cardiac myocytes. No DTEF-1 could be detected above background in western blots of nuclear extracts from these cells (data not shown). However, DTEF-1 was detected in these cells in a gel mobility supershift assay and accounted for up to 5% of the C2 MCAT-binding complex (Fig.   4 ).
To confirm that DTEF-1 is phosphorylated in neonatal rat cardiac myocytes and is a target of α 1 -adrenergic signaling-induced protein kinases, an epitope-tagged DTEF-1 construct was made. HA-tagged DTEF-1 protein was immunoprecipitated from nuclear extracts of cardiac myocytes treated with a vitamin C vehicle or the α 1 -adrenergic agonist phenylephrine. Western blot analysis shows that the 56 kDa protein is detected only in the DTEF-HA-transfected cardiac myocytes and not in the CMV-transfected myocytes ( signal was also increased such that the signal to noise ratio was essentially unchanged. Thus, it is difficult to say whether α 1 -adrenergic stimulation further phosphorylates DTEF-1. Given that 5 of the 9 putative phosphorylation targets of DTEF-1 are MAPK or PKC sites, these sites might be phosphorylated after α 1 -adrenergic stimulation. However, 4 of the 9 sites are GSK3 sites that conversely might be dephosphorylated after α 1 -adrenergic stimulation. Evidence that any of these sites plays a role in mediating α 1 -adrenergic signaling through DTEF-1 would require an exhaustive site-directed mutagenesis whose results might be equivocal. Given that DTEF-1 is phosphorylated in vivo, and that changes in phosphorylation alter its DNA binding properties (see Fig. 6 ), α 1 -adrenergic signaling is likely to affect DTEF-1 function directly. 
Discussion
The TEF-1 family of transcription factors plays several important roles in the regulation of gene expression. TEF-1 factors are implicated in the earliest stage of zygotic gene expression (26) , are involved in early nervous system development (15, 20) , and activate tissue-specific genes in the placenta (20, 27) , in skeletal muscle (28, 29) and in cardiac muscle (11, 30) . Moreover, TEF-1 factors are implicated in the activation of a number of genes in cardiac myocytes in response to exogenous growth factors including transforming growth factor β (31), catecholamines (4, 8, 10) and hypertrophic stresses (32).
Catecholamines bind to adrenergic receptors and activate signaling pathways that alter protein phosphorylation and change gene transcription. In a healthy heart, β-adrenergic receptor signaling is the main regulator of cardiac function that increases heart rate, the force of contraction In a diseased heart, the reduced response to β-adrenergic receptor signaling makes α 1 -adrenergic signaling more prevalent. 
